Table 2.

Age- and sex-adjusted relative levels of serum YKL-40 and IL-6 in healthy subjects (n = 245 for YKL-40 and n = 348 for IL-6) and patients with pretreatment (n = 176) and treated (n = 29) Hodgkin lymphoma

YKL-40IL-6
Healthy controls
    Increase per decade1.15 (1.12-1.19)1.07 (1.00-1.15)
    Males compared with females0.92 (0.82-1.04)1.15 (0.98-1.34)
Relative serum levels in pretreatment patients with HL compared with healthy controls*
    Overall HL3.63 (3.10-4.24)8.32 (5.94-11.7)
        Histology
            Nodular sclerosis3.73 (3.13-4.46)9.00 (6.26-12.9)
            Mixed cellularity3.15 (1.93-5.14)8.42 (3.28-21.6)
            Other/undefined3.40 (2.32-4.98)6.06 (1.91-19.2)
        Ann Arbor stage
            I3.42 (2.35-4.98)8.28 (2.60-26.4)
            II3.28 (2.74-3.92)5.95 (3.91-9.06)
            III4.23 (2.89-6.20)14.97 (7.28-30.8)
            IV4.20 (2.24-7.90)20.42 (6.58-63.4)
Ptrend < 0.0001Ptrend = 0.013
Serum level ≥6 months after treatment onset compared with pretreatment level (%)
    Overall HL70 (53-91)47 (26-83)
        Nodular sclerosis69 (50-95)30 (15-58)
        Mixed cellularity79 (44-141)98 (33-291)
        Other/undefined52 (24-113)112 (11-1152)
  • NOTE: For reference, relative levels were compared with serum levels estimated for healthy 35-year-old women: 39 ng/mL for YKL-40 and 1.3 pg/mL for IL-6.

  • * Relative to age- and sex-adjusted levels in healthy controls.

  • Difference relative to median serum levels in untreated patients after age and sex adjustment. For example, in Hodgkin lymphoma patients, median levels for YKL-40 were 70% of those seen in pretreatment patients after age and sex adjustment.